Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06675864 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS)

Name: Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS) — clinical trial record (NCT06675864)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusActive, Not Recruiting

PhasePhase 1/2

SponsorNovartis Pharmaceuticals

Started2024-12-12

View on ClinicalTrials.gov ↗

This is an open-label, multi-center, non-confirmatory study to assess the safety, disease progression, and cellular kinetics following YTB323 administration to 28 participants with non-active Progressive Multiple Sclerosis (PMS). The study design utilizes an ascending single dose design consisting of 3 sentinel cohorts followed by an expansion cohort.

Amendment history 1 change detected by DataLookout

2026-09-05

Enrollment closed, study ongoing

Trial Details

NCT Number	NCT06675864
Lead Sponsor	Novartis Pharmaceuticals
Conditions	Progressive Multiple Sclerosis
Enrollment	28 participants
Start Date	2024-12-12
Primary Completion	2030-06-14 (estimated)
Study Completion	2030-06-14 (estimated)
Updated on ClinicalTrials.gov	2026-09-04